Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
4.9
Journals
IJMS
Special Issues
Steatotic Liver Disease: From Bench to Bedside and Back
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Steatotic Liver Disease: From Bench to Bedside and Back

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 June 2025) | Viewed by 708

Special Issue Editor

Dr. Federico Salomone

E-Mail Website
Guest Editor
Division of Gastroenterology, Ospedale di Acireale, Azienda Sanitaria Provinciale di Catania, 95123 Catania, Italy
Interests: metabolic syndrome; insulin resistance; chronic hepatitis C; liver; antioxidants; mesenchymal stem cell; inflammatory biomarkers; liver diseases; fatty liver; diabetes; hepatitis; cirrhosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Steatotic Liver Disease (SLD), including Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-associated Liver Disease (ALD) and the mixed form MetALD, represents a major health concern wordwide. In the last years, the burden of liver-related morbidity and mortality is rapidly growing especially because of the global epidemic of SLD. Translational research aims to identify molecular mechanisms relevant to the pathogenesis of diseases in order to discover novel therapeutic targets. This special issue will accept translational studies shedding light on the molecular bases of MASLD, ALD and MetALD with particular interest on the crosstalk between the liver and other organs (particularly the gut, the adipose tissue and the muscle). Translational studies in in vitro and in vivo models of SLD, focusing on glucose metabolism and insulin signaling, lipoprotein metabolism and lipotoxicity, oxidative stress and inflammation, fibrosis and oncogenesis, are welcome. Clinical studies identifying molecular markers for the prediction of liver outcomes are also welcome.

Dr. Federico Salomone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • MASLD
  • ALD
  • MetALD
  • fibrosis
  • hepatocellular carcinoma
  • molecular mechanisms
  • molecular markers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 3483 KiB  
Article
Levels of Growth Differentiation Factor 15 Correlated with Metabolic Dysfunction-Associated Steatotic Liver Disease in Children
by Antonella Mosca, Maria Rita Braghini, Giulia Andolina, Cristiano De Stefanis, Lucia Cesarini, Anna Pastore, Donatella Comparcola, Lidia Monti, Paola Francalanci, Clara Balsano, Andrea Pietrobattista, Anna Alisi and Nadia Panera
Int. J. Mol. Sci. 2025, 26(13), 6486; https://doi.org/10.3390/ijms26136486 - 5 Jul 2025
Viewed by 179
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic progressive hepatopathy in children, and the identification of non-invasive biomarkers is urgently needed. Growth differentiation factor 15 (GDF15) was associated with MASLD in adults. In this study, we investigated the circulating and [...] Read more.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic progressive hepatopathy in children, and the identification of non-invasive biomarkers is urgently needed. Growth differentiation factor 15 (GDF15) was associated with MASLD in adults. In this study, we investigated the circulating and hepatic levels of GDF15 and their association with liver damage in pediatric MASLD and in a murine model. This observational study included 158 children with biopsy-proven MASLD. Patients with MASLD were categorized into two groups based on steatohepatitis (MASH) presence and evaluated for GDF15 circulating levels, while GDF15 hepatic levels were assessed only in a subset of patients. Children with MASLD exhibited higher levels of circulating GDF15 compared to the controls. Moreover, the MASH subgroup had significantly higher values of GDF15 compared to the Not-MASH subgroup. The GDF15 levels in the MASH subgroup showed a positive correlation with fibrosis. Finally, the hepatic expression of the GDF15 gene correlated with GDF15 circulating levels and with the hepatic expression of the COL1A1 and COL3A1 genes in 15 children with MASLD. In conclusion, our study demonstrated that GDF15 levels are associated with liver damage, reinforcing the potential role of GDF15 as a biomarker for MASLD-related fibrosis in children. Full article
(This article belongs to the Special Issue Steatotic Liver Disease: From Bench to Bedside and Back)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

27 pages, 1975 KiB  
Review
Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives
by Krzysztof Drygalski
Int. J. Mol. Sci. 2025, 26(13), 6518; https://doi.org/10.3390/ijms26136518 - 7 Jul 2025
Viewed by 201
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, is the most prevalent chronic liver disease worldwide. Strongly linked to obesity, type 2 diabetes, and metabolic syndrome, MASLD poses a growing health burden. Despite its high prevalence and risk of progression, no pharmacological treatment [...] Read more.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, is the most prevalent chronic liver disease worldwide. Strongly linked to obesity, type 2 diabetes, and metabolic syndrome, MASLD poses a growing health burden. Despite its high prevalence and risk of progression, no pharmacological treatment is currently approved. This narrative review provides an overview of emerging pharmacological treatments under clinical investigation, with a particular focus on agents recently evaluated in randomized clinical trials. A systematic search of the ClinicalTrials.gov database through to April 2025 was conducted to identify relevant studies. Investigational drugs were categorized by their molecular mechanisms, and data on efficacy, safety, and clinical development phases were summarized. The most extensively studied drug classes include GLP-1 receptor agonists, PPAR agonists, and FXR agonists, as well as inhibitors of ACC and DGAT. These therapies have shown promising effects on hepatic steatosis, liver enzyme levels, and metabolic markers and may be introduced into clinical practice in the near future. Full article
(This article belongs to the Special Issue Steatotic Liver Disease: From Bench to Bedside and Back)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop